Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

Materials and methods for diagnosis, prognosis and assessment of therapeutic/prophylactic treatment of prostate cancer

  • CN 104,011,227 A
  • Filed: 12/20/2012
  • Published: 08/27/2014
  • Est. Priority Date: 12/30/2011
  • Status: Active Application
First Claim
Patent Images

1. the method that detects the prostate cancer in patient, described method comprises:

  • Under hybridization conditions, the prostatic cell sample from described patient is contacted with the probe groups of detectable label, the probe groups of described detectable label comprises for the locus-specific probe of MYC, for the locus-specific probe of Phosphoric acid esterase and tensin homologue (PTEN), for No. 8 chromosomal centromeric probes with for No. 7 chromosomal centromeric probes, existence with definite chromosome abnormaltyThe MYC % that is wherein greater than 35 (scope is 2 to

         50) in the prostatic cell sample from the prostatic tumour of described patient target area (ROI) or optimum ROI increases (it is the % with the cell of 2 signals of MYC >

    that % increases), the PTEN % that is greater than 33 (scope is 29 to

         33) loses (it is the % with the cell of 2 signals of <

    that % loses), No. 7 karyomit(e) % that No. 8 karyomit(e) % that are greater than 34 (scope is 32 to

         34) increase (it is the % with the cell of 2 signals of >

    that % increases) and are greater than 28 (scope is 24 to

         29) extremely (% is the % with the cell of 2 of >

    or 2 signals of <

    extremely) show that described patient has prostate cancer,Therefore the prostate cancer in described patient is detected.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×